An effective patent strategy depends on a timely understanding of the constantly changing IP and scientific landscape.

Patentability analysis

Patents cover processes, machines, methods of manufacture, compositions of matter, or improvements to any of them. 

To earn a patent, an invention must also clear four separate legal hurdles, and it must clear all of them, not just one. A brilliant, commercially valuable discovery can still fail if it stumbles at a single gate. Preparation is key. 

Patentability requirements shape how an invention should be envisioned, documented, and claimed from the earliest stages. Understanding them early can be the difference between a defensible patent application and a costly rejection. 

Think of patentability as four questions, each of which must be answered “yes.”

1. Is it a Patentable Subject Matter?

Patent laws do not permit patents on laws of nature, natural phenomena, or abstract ideas. The way an invention is framed, natural product versus engineered innovation, can determine whether or not it is patent eligible.

2. Is it useful? (Utility)

The invention must have a specific, substantial, and credible use. For most inventions, this is easily met, but in biotechnology the Patent Office looks carefully at whether a claimed sequence or protein has a genuine, disclosed real-world application, not merely a speculative one. A gene of unknown function is a common casualty here.

3. Is it new? (Novelty)

The invention must be new. If a single earlier source, a publication, a prior patent, or a public disclosure anywhere in the world already describes every element of your invention, it is not novel and cannot be patented.

Two points matter greatly:

  • The United States operates on a first inventor-to-file system. What matters is who files first, so timing is critical.
  • In the U.S., there is a one-year grace period for your own disclosures. If you present at a conference or publish a paper, you generally have twelve months to file before that disclosure counts against you. The grace period only applies to U.S. patent applications. Pre-filing disclosure forfeits rights in absolute-novelty jurisdictions, such as in Europe. This is one of the most common and most avoidable ways inventors lose their rights. When in doubt, file before you disclose.

4. Is it non-obvious? (Non-Obviousness)

Even if your invention is new, it must not have been obvious to a skilled person in the field at the time you filed. This is frequently the hardest requirement to satisfy.

Courts weigh several factors: the existing state of the art, how far your invention departs from it, the level of skill in the field, and real-world evidence such as commercial success, a long-felt but unmet need, or unexpected results.

Why this matters in biotech. Unexpected results and the question of whether success was predictable are often decisive. A therapeutic that shows surprising efficacy, or a class of compounds that would not have been expected to work, can overcome an obviousness challenge that might otherwise sink the claim. Documenting the surprising nature of your results early is imperative.

Clearing the four aforementioned requirements is not quite the whole story. A patentable invention must also be adequately described in the application itself. The law requires that you:

  • Describe the invention fully enough to show you truly possessed it (Written Description);
  • Enable others skilled in the field to make and use it without undue experimentation (Enablement); and
  • Claim it with precision, so the boundaries of your rights are clear (Definiteness).

A preliminary patentability analysis is strongly recommended to assess, at a minimum, whether the claimed invention is novel. This analysis provides guidance on those aspects of the invention disclosure that should be novel and informs an appropriate claim scope, potential design-around strategies if needed, and the level of description in the specification necessary to support the claims.

Freedom-to-operate analysis

Most people assume a patent gives them the right to make and sell their invention. It does not. A patent gives an applicant the right to exclude others from making, using, selling, offering to sell, or importing an invention for a limited period, typically 20 years from the time of filing. This is a negative right. It is a legal tool for keeping competitors out, not a permission slip for entering the market yourself.

Understanding this distinction is essential to using your patent portfolio strategically, especially in the life sciences, where inventions are frequently layered on top of one another, and freedom-to-operate is rarely straightforward.

It is therefore imperative to perform a preliminary freedom-to-operate analysis to determine if commercialization of Applicant’s invention could be blocked by one or more claims of a competitor’s patent and if the obstacle can be overcome with a licensing agreement or an assertion of invalidity.

Invalidity Analysis

Even if a blocking patent is discovered, the Applicant may want to determine if the patent can be invalidated, e.g., in a Post Grant Review (PGR) if within 9 months of issuance or in an Inter-Partes Review (IPR). One approach is to uncover a novelty-destroying publication that was not considered by the Examiner during examination and therefore not cited on the face of the patent.

The Importance of Due Diligence

An effective patent strategy depends on a timely understanding of the constantly changing IP and scientific landscape.

Patentability analysis

Patents cover processes, machines, methods of manufacture, compositions of matter, or improvements to any of them. 

To earn a patent, an invention must also clear four separate legal hurdles, and it must clear all of them, not just one. A brilliant, commercially valuable discovery can still fail if it stumbles at a single gate. Preparation is key. 

Patentability requirements shape how an invention should be envisioned, documented, and claimed from the earliest stages. Understanding them early can be the difference between a defensible patent application and a costly rejection. 

Think of patentability as four questions, each of which must be answered “yes.”

1. Is it a Patentable Subject Matter?

Patent laws do not permit patents on laws of nature, natural phenomena, or abstract ideas. The way an invention is framed, natural product versus engineered innovation, can determine whether or not it is patent eligible.

2. Is it useful? (Utility)

The invention must have a specific, substantial, and credible use. For most inventions, this is easily met, but in biotechnology the Patent Office looks carefully at whether a claimed sequence or protein has a genuine, disclosed real-world application, not merely a speculative one. A gene of unknown function is a common casualty here.

3. Is it new? (Novelty)

The invention must be new. If a single earlier source, a publication, a prior patent, or a public disclosure anywhere in the world already describes every element of your invention, it is not novel and cannot be patented.

Two points matter greatly:

  • The United States operates on a first inventor-to-file system. What matters is who files first, so timing is critical.
  • In the U.S., there is a one-year grace period for your own disclosures. If you present at a conference or publish a paper, you generally have twelve months to file before that disclosure counts against you. The grace period only applies to U.S. patent applications. Pre-filing disclosure forfeits rights in absolute-novelty jurisdictions, such as in Europe. This is one of the most common and most avoidable ways inventors lose their rights. When in doubt, file before you disclose.

4. Is it non-obvious? (Non-Obviousness)

Even if your invention is new, it must not have been obvious to a skilled person in the field at the time you filed. This is frequently the hardest requirement to satisfy.

Courts weigh several factors: the existing state of the art, how far your invention departs from it, the level of skill in the field, and real-world evidence such as commercial success, a long-felt but unmet need, or unexpected results.

Why this matters in biotech. Unexpected results and the question of whether success was predictable are often decisive. A therapeutic that shows surprising efficacy, or a class of compounds that would not have been expected to work, can overcome an obviousness challenge that might otherwise sink the claim. Documenting the surprising nature of your results early is imperative.

Clearing the four aforementioned requirements is not quite the whole story. A patentable invention must also be adequately described in the application itself. The law requires that you:

  • Describe the invention fully enough to show you truly possessed it (Written Description);
  • Enable others skilled in the field to make and use it without undue experimentation (Enablement); and
  • Claim it with precision, so the boundaries of your rights are clear (Definiteness).

A preliminary patentability analysis is strongly recommended to assess, at a minimum, whether the claimed invention is novel. This analysis provides guidance on those aspects of the invention disclosure that should be novel and informs an appropriate claim scope, potential design-around strategies if needed, and the level of description in the specification necessary to support the claims.

Freedom-to-operate analysis

Most people assume a patent gives them the right to make and sell their invention. It does not. A patent gives an applicant the right to exclude others from making, using, selling, offering to sell, or importing an invention for a limited period, typically 20 years from the time of filing. This is a negative right. It is a legal tool for keeping competitors out, not a permission slip for entering the market yourself.

Understanding this distinction is essential to using your patent portfolio strategically, especially in the life sciences, where inventions are frequently layered on top of one another, and freedom-to-operate is rarely straightforward.

It is therefore imperative to perform a preliminary freedom-to-operate analysis to determine if commercialization of Applicant’s invention could be blocked by one or more claims of a competitor’s patent and if the obstacle can be overcome with a licensing agreement or an assertion of invalidity.

Invalidity Analysis

Even if a blocking patent is discovered, the Applicant may want to determine if the patent can be invalidated, e.g., in a Post Grant Review (PGR) if within 9 months of issuance or in an Inter-Partes Review (IPR). One approach is to uncover a novelty-destroying publication that was not considered by the Examiner during examination and therefore not cited on the face of the patent.